Metropolitan Life Insurance Company (MetLife)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-7,999
Closed -$40.1K 208
2024
Q1
$40.1K Hold
7,999
﹤0.01% 1520
2023
Q4
$71.9K Hold
7,999
﹤0.01% 1255
2023
Q3
$62.2K Buy
7,999
+594
+8% +$5.81K ﹤0.01% 1276
2023
Q2
$71.7K Hold
7,405
﹤0.01% 1205
2023
Q1
$81.2K Sell
7,405
-859
-10% -$7.57K ﹤0.01% 1115
2022
Q4
$35.7K Hold
8,264
﹤0.01% 1685
2022
Q3
$62.1K Hold
8,264
﹤0.01% 1308
2022
Q2
$83.1K Buy
+8,264
New +$92.4K ﹤0.01% 1177

Other funds holding AUPH

Metropolitan Life Insurance Company (MetLife)'s AUPH Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 7,999 shares — an estimated $40.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AUPH in Q2 2022 and held it in 8 quarters. The position peaked at $83.1K in Q2 2022. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 7,999 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $40.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Aurinia Pharmaceuticals position peaked at $83.1K in Q2 2022.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.